DE2853453C2 - - Google Patents

Info

Publication number
DE2853453C2
DE2853453C2 DE2853453A DE2853453A DE2853453C2 DE 2853453 C2 DE2853453 C2 DE 2853453C2 DE 2853453 A DE2853453 A DE 2853453A DE 2853453 A DE2853453 A DE 2853453A DE 2853453 C2 DE2853453 C2 DE 2853453C2
Authority
DE
Germany
Prior art keywords
antibody
immune complexes
antibodies
composition according
clq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2853453A
Other languages
German (de)
English (en)
Other versions
DE2853453A1 (de
Inventor
Hans-Harald Dr. Sedlacek
Friedrich Robert Dr. 3550 Marburg De Seiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DE19782853453 priority Critical patent/DE2853453A1/de
Priority to EP79104819A priority patent/EP0012305B1/de
Priority to DE7979104819T priority patent/DE2964386D1/de
Priority to AT79104819T priority patent/ATE2049T1/de
Priority to US06/101,645 priority patent/US4479934A/en
Priority to CA000341535A priority patent/CA1135185A/en
Priority to NO794019A priority patent/NO794019L/no
Priority to IL58906A priority patent/IL58906A/xx
Priority to JP15986479A priority patent/JPS5581817A/ja
Publication of DE2853453A1 publication Critical patent/DE2853453A1/de
Application granted granted Critical
Publication of DE2853453C2 publication Critical patent/DE2853453C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE19782853453 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen Granted DE2853453A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE19782853453 DE2853453A1 (de) 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen
DE7979104819T DE2964386D1 (en) 1978-12-11 1979-12-01 Therapeutic means for immune complex diseases
AT79104819T ATE2049T1 (de) 1978-12-11 1979-12-01 Mittel zur therapie von immunkomplexerkrankungen.
EP79104819A EP0012305B1 (de) 1978-12-11 1979-12-01 Mittel zur Therapie von Immunkomplexerkrankungen
US06/101,645 US4479934A (en) 1978-12-11 1979-12-10 Method and agent for the therapy of immunocomplex diseases
CA000341535A CA1135185A (en) 1978-12-11 1979-12-10 Agent for the therapy of immunocomplex diseases
NO794019A NO794019L (no) 1978-12-11 1979-12-10 Middel til terapi av immunkomplekssykdommer.
IL58906A IL58906A (en) 1978-12-11 1979-12-10 Agent for the therapy of immunocomplex diseases
JP15986479A JPS5581817A (en) 1978-12-11 1979-12-11 Therapeutic drug for immunity compounded disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782853453 DE2853453A1 (de) 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen

Publications (2)

Publication Number Publication Date
DE2853453A1 DE2853453A1 (de) 1980-06-19
DE2853453C2 true DE2853453C2 (enExample) 1987-11-19

Family

ID=6056859

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19782853453 Granted DE2853453A1 (de) 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen
DE7979104819T Expired DE2964386D1 (en) 1978-12-11 1979-12-01 Therapeutic means for immune complex diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE7979104819T Expired DE2964386D1 (en) 1978-12-11 1979-12-01 Therapeutic means for immune complex diseases

Country Status (8)

Country Link
US (1) US4479934A (enExample)
EP (1) EP0012305B1 (enExample)
JP (1) JPS5581817A (enExample)
AT (1) ATE2049T1 (enExample)
CA (1) CA1135185A (enExample)
DE (2) DE2853453A1 (enExample)
IL (1) IL58906A (enExample)
NO (1) NO794019L (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
JPH0643343B2 (ja) * 1984-12-28 1994-06-08 株式会社ミドリ十字 免疫調節剤
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
US5422258A (en) * 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH392780A (de) * 1961-12-07 1965-05-31 Schweiz Rotes Kreuz Verfahren zur Herstellung von intravenös anwendbaren Antikörperpräparaten humanen Ursprungs
US3466368A (en) * 1967-06-02 1969-09-09 Us Health Education & Welfare Cleavage of human gamma globulin by means of cyanogen bromide
GB1508132A (en) * 1974-05-20 1978-04-19 Technicon Instr Analysis of biological fluids
FR2279419A1 (fr) * 1974-07-25 1976-02-20 Merieux Inst Procede de preparation d'immunoglobulines purifiees, immunoglobulines purifiees obtenues et un medicament comprenant ces immunoglobulines purifiees
DE2658334C3 (de) * 1976-12-23 1987-05-07 Behringwerke Ag, 3550 Marburg Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen

Also Published As

Publication number Publication date
IL58906A0 (en) 1980-03-31
US4479934A (en) 1984-10-30
DE2964386D1 (en) 1983-01-27
NO794019L (no) 1980-06-12
ATE2049T1 (de) 1983-01-15
EP0012305A1 (de) 1980-06-25
CA1135185A (en) 1982-11-09
EP0012305B1 (de) 1982-12-22
IL58906A (en) 1982-11-30
DE2853453A1 (de) 1980-06-19
JPS5581817A (en) 1980-06-20

Similar Documents

Publication Publication Date Title
DE68928427T2 (de) Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
DE69132045T2 (de) Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha
DE3688637T2 (de) Löslicher Interleukin-2-Rezeptor als Anzeiger eines bösartigen Tumors und Verfahren zu dessen Nachweis.
DE3486030T2 (de) Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
DE3752129T2 (de) Verwendung eines gegen das 17-1A Antigen gerichteten monoklonalen Antikörpers zur Herstellung eines Arzneimittels für die Behandlung von einem Magen-Darm-Tumor
DE2846412C2 (enExample)
DE2853453C2 (enExample)
DE69425246T2 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE69029808T2 (de) Monoklonale antikörper
DE3785967T2 (de) Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
DE69125485T2 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
DE69008535T2 (de) Humane antigammainterferonantikörper, welche detektiert und geklärt sind mit verwendung von synthetischen peptiden.
DE3689779T2 (de) Plättcheninhibierender Teil eines monoklonalen Antikörpers.
DE2639012C3 (de) Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen
DE69120463T2 (de) Verfahren zum Nachweis der Erythrozytenagglutination zur Feststellung der Blutverträglichkeit
CH632091A5 (en) Process for the preparation of an antiserum directed against placenta-specific glycoprotein
DE4130221C2 (de) Verwendung von proteolytischen Enzymen zur Herstellung eines Medikaments zur Behandlung von Autoimmun-Krankheiten, an deren Entstehung Proteine mit einer C¶H¶2-Domäne beteiligt sind
CH639394A5 (de) Verfahren zur herstellung von immunglobulinpraeparationen mit verminderter komplementaktivitaet.
Stracke et al. Characterization of monoclonal antibodies produced by immunization with partially purified IgE receptor complexes
CH392780A (de) Verfahren zur Herstellung von intravenös anwendbaren Antikörperpräparaten humanen Ursprungs
DE68929127T2 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden
DE3609271A1 (de) Verfahren und reagenz zum nachweis von autoimmunerkrankungen, arzneimittel zur behandlung von autoimmunerkrankungen sowie hierzu geeignete antiparatypische antikoerper
EP1025854A1 (de) Verwendung depletorisch oder mitogen wirkender Antikörper gegen CD3/TCR in der Immuntherapie
DE2533183C3 (de) Verfahren zum Herstellen gereinigter Immunglobuline
EP1025855A1 (de) Arzneimittel enthaltend Anti-CD3 und Anti-Fcy-R-Antikörper zur begleitenden Behandlung bei Organtransplantationen

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee